Mar. 27 at 12:47 PM
Novartis will acquire U.S.-based biotech Excellergy for up to
$2B, adding early-stage allergy drug candidate Exl-111 to its portfolio as it prepares for upcoming patent expirations. The deal includes upfront and milestone payments and is expected to close in the first half of 2026, pending regulatory approval.
The move follows a separate agreement just a week earlier to acquire Pikavation Therapeutics for up to
$3B, highlighting Novartis’ strategy of targeted bolt-on acquisitions to strengthen its pipeline. The company has also recently expanded into other therapeutic areas, aiming to secure future growth.
These deals come as the pharmaceutical industry faces a looming “patent cliff,” with major drugs losing exclusivity and exposing revenues to generic competition. Novartis expects pressure from key products going off patent but is offsetting this with growth in newer medicines and continued pipeline expansion.
$NVS $GSK $AZN